Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome/LabCorp’s MGMT Test

Premium
Laboratory Corporation of America this week commercially launched its MGMT methylation testing service to gauge patients’ responsiveness to cancer therapies. 
 
For the test, LabCorp licensed OncoMethylome's MSP and MGMT DNA methylation marker technology.
 
OncoMethylome Sciences will receive royalty and milestone payments from LabCorp on the sales of the MGMT methylation testing service. Financial terms of the deal were not announced.
 
While its deal with LabCorp is for the North American market, OncoMethylome noted that efforts are underway to extend commercial availability of its technology to the European markets.

Filed under

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.